Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
10-Propargyl-5,8-dideazafolic acid (CB3717) is a small molecule antifolate compound that acts as a potent inhibitor of thymidylate synthase. By inhibiting this enzyme, it disrupts the synthesis of thymidine monophosphate (dTMP), an essential precursor for DNA biosynthesis. This mechanism targets folate-dependent biological pathways and has been investigated primarily in the context of cancer therapy due to its ability to inhibit cell proliferation. The drug is considered experimental and has been studied for its effects on leukemia cell lines resistant to other antifolates such as methotrexate and trimetrexate[2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 10-Propargyl-5,8-dideazafolic acid.